Mylan Competitors and Similar CompaniesClear all
Mylan's competitors and similar companies include Amgen, BioMarin Pharmaceutical and Cipla.
 Mylan Mylan is a global pharmaceutical company, which develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  BioMarin Pharmaceutical BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. | |
Founding Date | Founding Date 1961 | Founding Date 1980 | Founding Date 1997 | Founding Date 1935 |
Type | Type Subsidiary | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Canonsburg, US HQ Hatfield, GB | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations San Rafael, US HQ Martínez, AR Crows Nest, AU Sao Paulo, BR Bogotá, CO Kronberg Im Taunus, DE Wanchai, HK see more | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more |
Employees | Employees 35,000 | Employees 25,200 | Employees 3,0015% increase | Employees 27,764 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 170.4 b | Valuation ($) 13.3 b | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) $11.1b (FY, 2016) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $3.2b (FY, 2025) | Revenue (est.) ₹277.1b (FY, 2026) |
Cost of goods | Cost of goods $6.4b (FY, 2016) | Cost of goods $12b (FY, 2025) | Cost of goods $717.4m (FY, 2025) | Cost of goods ₹95.5b (FY, 2026) |
Gross profit | Gross profit $4.7b (FY, 2016) | Gross profit $24.7b (FY, 2025) | Gross profit $2.5b (FY, 2025) | Gross profit ₹195b (FY, 2026) |
Net income | Net income $480m (FY, 2016) | Net income $7.7b (FY, 2025) | Net income $348.9m (FY, 2025) | Net income ₹38.7b (FY, 2026) |
Operating ⚠ | ||||
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products N/A |
For sources of this data, please see the company profile
View Company Profiles
Amgen
HQ
Thousand Oaks, US
Employees
25,200
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
View companyBioMarin Pharmaceutical
HQ
San Rafael, US
Employees
3,001↑ 5% increase
BioMarin develops and provides innovative biopharmaceuticals for serious diseases and medical conditions.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View company